接受基于曲妥珠单抗治疗的转移性乳腺癌患者的脑转移

Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapies.

作者信息

Puente Vázquez Javier, López-Tarruella Cobo Sara, García-Sáenz José A, Casado Herráez Antonio, Moreno Antón Fernando, Sampedro Gimeno Teresa, Bueno Muiño Coralia, Grande Pulido Enrique, Martín Jiménez Miguel, Díaz-Rubio Eduardo

机构信息

Servicio de Oncología Médica, Hospital Clínico San Carlos, Madrid, Spain.

出版信息

Clin Transl Oncol. 2006 Jan;8(1):50-3. doi: 10.1007/s12094-006-0095-8.

DOI:10.1007/s12094-006-0095-8

PMID:16632440

Abstract

INTRODUCTION

CNS metastases mean a great challenge. It has been suggested that the brain metastases incidence could be high in metastasic breast cancer patients receiving trastuzumab based-therapies.

MATERIAL AND METHODS

We performed a descriptive analysis of our experience in this setting. 86 patients met the criteria (From Oct/99 to Oct/03).

RESULTS

CNS progression occurred in 17 patients (19.5%). Mean age of CNS progression disease patients was 45.4 years while mean age for all the patients was 50.5 years. Response rate for the entire group of patients was: OR 39.7%; CB (OR + SD) 69%. Response rate to trastuzumab based-therapy was OR 82.4% and CB 88.2 at the time of CNS progression. Median time from the start of trastuzumab therapy up to the CNS progression was 10 months. OS was 23.4 weeks.

CONCLUSIONS

The incidence of CNS involvement is high in young metastasic breast cancer women responding to trastuzumab-based therapies. This may lead to prophylactic cranial irradiation strategies or to the early detection in asymptomatic patients to improve surgery or radiosurgery results in these patients.

摘要

引言

中枢神经系统转移意味着巨大挑战。有人提出，接受曲妥珠单抗治疗的转移性乳腺癌患者脑转移发生率可能较高。

材料与方法

我们对在这种情况下的经验进行了描述性分析。86例患者符合标准（从1999年10月至2003年10月）。

结果

17例患者（19.5%）发生中枢神经系统进展。中枢神经系统进展疾病患者的平均年龄为45.4岁，而所有患者的平均年龄为50.5岁。整个患者组的缓解率为：客观缓解率（OR）39.7%；临床受益率（CB，OR+稳定疾病）69%。在中枢神经系统进展时，基于曲妥珠单抗治疗的缓解率为OR 82.4%，CB 88.2%。从开始曲妥珠单抗治疗到中枢神经系统进展的中位时间为10个月。总生存期为23.4周。